United States · Bill · S
S. 1801 (116th)
Affordable Medications Act
Introduced
12 June 2019
Last action
12 June 2019 · Introduced
Status
Read twice and referred to the Committee on Finance.
Sponsors
Sen. Smith, Tina [D-MN], Sen. Klobuchar, Amy [D-MN], Sen. Blumenthal, Richard [D-CT], Sen. Udall, Tom [D-NM], Sen. Brown, Sherrod [D-OH], Sen. Warren, Elizabeth [D-MA], Sen. Sanders, Bernard [I-VT], Sen. Hassan, Margaret Wood [D-NH], Sen. Whitehouse, Sheldon [D-RI], Sen. Merkley, Jeff [D-OR], Sen. Reed, Jack [D-RI], Sen. Baldwin, Tammy [D-WI], Sen. Booker, Cory A. [D-NJ], Sen. Durbin, Richard J. [D-IL], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Harris, Kamala D. [D-CA]
Subjects
Healthcare, Taxation
Source updated
3 January 2025
Summary
Affordable Medications Act This bill revises and expands various requirements relating to prescription-drug pricing and affordability. Specifically, the bill expands financial reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans and group health plans; modifies requirements for the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; limits the time frame that trade agreements are required to provide market exclusivity for biological products; establishes an innovation incentive fund for new or more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; revises certain time frames and conditions related to drug exclusivity; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
12 June 2019
Introduced
Read twice and referred to the Committee on Finance.
Source: IntroReferral
12 June 2019
Introduced
Introduced in Senate
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
- Introduced in Senate · 12 June 2019 · Download file
Documents
3 official files
Introduced in Senate (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in Senate (text)
Introduced in Senate · EN · 12 June 2019
Introduced in Senate (PDF)
Introduced in Senate · EN · 12 June 2019
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in Senate
summary · EN · 12 June 2019
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Sen. Smith, Tina [D-MN] · D · Sponsor
- Sen. Klobuchar, Amy [D-MN] · D · Sponsor
- Sen. Blumenthal, Richard [D-CT] · D · Sponsor
- Sen. Udall, Tom [D-NM] · D · Sponsor
- Sen. Brown, Sherrod [D-OH] · D · Sponsor
- Sen. Warren, Elizabeth [D-MA] · D · Sponsor
- Sen. Sanders, Bernard [I-VT] · I · Sponsor
- Sen. Hassan, Margaret Wood [D-NH] · D · Sponsor
- Sen. Whitehouse, Sheldon [D-RI] · D · Sponsor
- Sen. Merkley, Jeff [D-OR] · D · Sponsor
- Sen. Reed, Jack [D-RI] · D · Sponsor
- Sen. Baldwin, Tammy [D-WI] · D · Sponsor
- Sen. Booker, Cory A. [D-NJ] · D · Sponsor
- Sen. Durbin, Richard J. [D-IL] · D · Sponsor
- Sen. Gillibrand, Kirsten E. [D-NY] · D · Sponsor
- Sen. Harris, Kamala D. [D-CA] · D · Cosponsor
- · ssfi00 · Standing
Related records
- related to → Affordable and Safe Prescription Drug Importation Act
- related to → Stop Price Gouging Act
- related to → FAIR Generics Act
- related to → End Taxpayer Subsidies for Drug Ads Act
- related to → Affordable and Safe Prescription Drug Importation Act
- related to → Stop Price Gouging Act
- related to → Fair AMP Act
- related to → Preserve Access to Affordable Generics and Biosimilars Act
- related to ← End Taxpayer Subsidies for Drug Ads Act
- related to ← Affordable Medications Act
Showing 10 of 12 related records.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/senate-bill/1801
- Open data entity: https://api.congress.gov/v3/bill/116/s/1801
- us · 116-s-1801 · source updated 3 January 2025